Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512484-31-00

Enrollment

146

Registered

2024-11-01

Start date

2025-02-28

Completion date

Unknown

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

Brief summary

Objective response rate (ORR), defined as proportion of subjects with a complete response (CR) or partial response (PR) according to RECIST v1.1, for each cohort (cohort 1 – bemarituzumab plus irinotecan, cohort 2 – bemarituzumab plus paclitaxel and ramucirumab, cohort 3 – bemarituzumab plus trifluridine/tipiracil)

Interventions

DRUGIRINOTECAN

DRUGRAMUCIRUMAB

DRUGBemarituzumab

DRUGPACLITAXEL

DRUGLonsurf 15 mg/6.14 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR), defined as proportion of subjects with a complete response (CR) or partial response (PR) according to RECIST v1.1, for each cohort (cohort 1 – bemarituzumab plus irinotecan, cohort 2 – bemarituzumab plus paclitaxel and ramucirumab, cohort 3 – bemarituzumab plus trifluridine/tipiracil)	—

Countries

Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026